Similar articles

• Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program.

  Tosoian JJ, Loeb S, Kettermann A, Landis P, Elliot DJ, Epstein JI, Partin AW, Carter HB, Sokoll LJ. Tosoian JJ, et al. J Urol. 2010 Feb;183(2):534-8. doi: 10.1016/j.juro.2009.10.003. Epub 2009 Dec 14. J Urol. 2010. PMID: 20006883
• Re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009;56:659-68.

  Morote J. Morote J. Eur Urol. 2010 Jan;57(1):e1; author reply e2-3. doi: 10.1016/j.eururo.2009.09.041. Epub 2009 Oct 9. Eur Urol. 2010. PMID: 19853371 No abstract available.
• Re: Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. A. S. Duffield, T. K. Lee, H. Miyamoto, H. B. Carter and J. I. Epstein. J Urol 2009; 182: 2274-2278.

  Lawrentschuk N, Fleshner NE. Lawrentschuk N, et al. J Urol. 2010 May;183(5):2099. doi: 10.1016/j.juro.2010.01.038. Epub 2010 Mar 19. J Urol. 2010. PMID: 20303514 No abstract available.
• [Value of urinary PCA3 test for prostate cancer diagnosis].

  Vlaeminck-Guillem V, Ruffion A, Andre J. Vlaeminck-Guillem V, et al. Prog Urol. 2008 May;18(5):259-65. doi: 10.1016/j.purol.2008.03.029. Epub 2008 May 16. Prog Urol. 2008. PMID: 18538269 Review. French.
• The Prostate Cancer gene 3 assay: indications for use in clinical practice.

  Schilling D, de Reijke T, Tombal B, de la Taille A, Hennenlotter J, Stenzl A. Schilling D, et al. BJU Int. 2010 Feb;105(4):452-5. doi: 10.1111/j.1464-410X.2009.09085.x. Epub 2009 Nov 20. BJU Int. 2010. PMID: 19930176 Review.